AH Equity Partners Bio I, L.L.C. - 15 Oct 2024 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role: 10%+ Owner
Signature: AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P., By: AH Equity Partners Bio I, L.L.C., its General Partner, By: /s/ Scott Kupor, Authorized Signatory
Issuer symbol: CAMP
Transactions as of: 15 Oct 2024
Net transactions value: +$7,999,992
Form type: 4
Filing time: 17 Oct 2024, 17:05:20 UTC
Previous filing: 10 Oct 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CAMP	Common Stock	Conversion of derivative security		+1,398,067			1,398,067	15 Oct 2024	By AH Bio Fund I, L.P., as nominee	F1, F2
transaction	CAMP	Common Stock	Purchase	$1,999,998	+181,818	+13%	$11.00	1,579,885	15 Oct 2024	By AH Bio Fund I, L.P., as nominee	F2
transaction	CAMP	Common Stock	Purchase	$5,999,994	+545,454		$11.00	545,454	15 Oct 2024	By AH Bio Fund IV, L.P., as nominee	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CAMP	Series A Prime Preferred Stock	Conversion of derivative security		-15,001,312	-100%		0	15 Oct 2024	Common Stock	1,337,513		By AH Bio Fund I, L.P., as nominee	F1, F2
transaction	CAMP	Series B Preferred Stock	Conversion of derivative security		-679,163	-100%		0	15 Oct 2024	Common Stock	60,554		By AH Bio Fund I, L.P., as nominee	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
F2	These shares are held of record by AH Bio Fund I, L.P. ("AH Bio I") for itself and as nominee for AH Bio Fund I-B, L.P. AH Equity Partners Bio I, L.L.C. ("AH EP Bio I"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
F3	These shares are held of record by AH Bio Fund IV, L.P. ("AH Bio IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP (collectively, the "AH Bio Fund IV Entities"). AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV"), the general partner of AH Bio IV, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio IV, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio IV and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.